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Introduction 
Activation of T lymphocytes leads to the expression 
of interleukin-2 receptors (IL-2R) on the cell surface 
(1) as well as the release of soluble IL-2R (sIL-2R) 
molecules into the circulation (2). T lymphocytes are 
the predominant IL-2R bearing cells (3) and hence 
serum sIL-2R level provides a satisfactory indicator of 
T-cell activation in vivo. 
Elevated serum levels of sIL-2R have been reported 
in patients with small-cell lung cancer (4) (SCLC) and 
non-SCLC (5). Herein, we report a study designed 
to find out the sIL-2R concentrations in patients 
with non-SCLC and their changes following surgical 
resection. 
Patients and Methods 
Our sample population consisted of 59 consecutive 
patients with primary lung cancer (28 adenocarcinoma, 
19 squamous cell carcinoma, four undifferentiated 
carcinoma and 8 SCLC). 
Twenty-six patients had clinically operable non- 
SCLC and underwent surgical operation. However, 
only 13 patients (eight adenocarcinoma and five 
squamous cell carcinoma) had limited intrathoracic 
disease at operation and resection of tumour was per- 
formed. In 12 cases, extensive intrathoracic disease 
was found at operation including lymph nodes, 
superior vena cava and chest wall invasion and 
complete resection of tumour was not possible. One 
patient had complete resection of the lung tumour but 
was found to have brain metastasis 2 months after 
operation. 
Eighteen patients with non-SCLC had distant 
metastasis detected on investigation and operation was 
not performed (ten adenocarcinoma, six squamous 
cell, two undifferentiated). The sites of metastasis 
included: four lymph node; three bone; five pleura; 
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one brain; one pulmonary; one pericardium and three 
multiple sites. Seven patients had clinically localized 
disease but were inoperable because of poor lung 
function. Eight patients had SCLC and surgery was 
not considered. 
Serum samples were taken from the patients before 
chemotherapy or surgical treatment was initiated. In 
patients with complete resection of tumour, serum 
samples were taken again at 3 weeks and 3 months 
after operation. Control serum samples were also 
taken from 41 normal healthy subjects. All serum 
samples were randomly assigned code numbers and 
assayed in a single batch without the knowledge of the 
clinical status of the patients, disease staging, tumour 
histology or treatment modality. Serum sIL-2R con- 
centrations were measured by a modified ELISA 
method as previously described (6). 
Results 
The serum sIL-2R levels of the different groups of 
patients are shown in Fig. 1. The sIL-2R levels in the 59 
patients with lung cancer were significantly higher 
than those in control subjects (804.4 f 63.6 U ml-’ vs. 
374.2 f 29.9 Uml-‘, P< 0.0001). Similarly, the sIL-2R 
levels in 51 patients with non-SCLC (782.7f 59.9 U 
mll’) and in eight patients with SCLC (943.2+ 
283.5 U ml-‘) were significantly higher than those in 
control subjects (P < 0.000 1 and P < 0.02 respectively). 
However, no significant difference was demonstrated 
between the sIL-2R levels in SCLC and non-SCLC 
(P’O.79). 
The mean sIL-2R level in 18 patients with metastatic 
adenocarcinoma was 747.9 f 79.6 U ml-’ which was 
not significantly different from that in eight subjects 
with resectable adenocarcinoma (516.4&- 71.8 U ml-‘, 
P=O.l4). Similarly, the mean sIL-2R level in ten 
subjects with metastatic squamous-cell tumour was 
not significantly different from that in five subjects 
with resectable squamous cell lung cancer (739.9f 
62.1 Umllr vs. 704.2f85.4UmllI, P=O.27). 
@ 1993 BailliZre Tindall 
384 C. H. S. Chan et al. 
2 I 
d v el I 
g 100 
d 
1 
10 L 
P < 0~0001 
I'1 
B 0 q 0 
q 
-----II 
Control All AC see SCLC UD 
(n = 41) P”“;; (n = 28)(n = 19) (n = 8) (n = 4) 
n 
Fig. I Serum sIL-2R levels in patients with lung cancer and 
healthy controls. AC, adenocarcinoma; SCC, squamous-cell 
carcinoma; SCLC, small-cell lung cancer; UC, undifferentiated 
carcinoma. 
Table I Serum sIL-2R levels in 12 patients with extensive 
intrathoracic disease and 13 patients with localized tumour 
detected at thoracotomy. AC, adenocarcinoma; SCC, 
squamous-cell carcinoma; UD, undifferentiated carcinoma 
Extensive disease* Limited disease? 
481 
837 i::; 
883 (AC) 
460 (AC) 
1053 (AC) 626 (AC) 
1478 (AC) 442 (AC) 
1254 (AC) 565 (AC) 
967 (AC) 595 (AC) 
759 (AC) 198 (AC) 
818 (SCC) 362 (AC) 
625 (SCC) 939 (SCC) 
725 (SCC) 853 (SCC) 
32g :“u”D”: 
691 (SCC) 
2307 721 WC) 
692 (SCC) 
Mean 969.4 
@EM) (151.9)f 
*n= 12, tn= 13, JP=O.O39. 
617.5 
ww$ 
Twenty-six patients had undergone surgical oper- 
ation. Twelve of them were found to have extensive 
intrathoracic disease at operation and their serum sIL- 
2R levels (Table 1) were significantly higher than those 
of 13 subjects with resectable tumour (969.4 f 15 1.9 VS. 
617.5+ 59.4 U ml-‘, P=O.O39). If we take the normal 
range of sIL-2R as mean + 2 SD of the normal control 
values, then nine of the twelve cases (75%) with exten- 
sive intrathoracic disease had sIL-2R levels above the 
upper limit of normal range. In contrast, in the 13 
patients with resectable tumour, only four (3 1%) had 
marginally raised sIL-2R levels while the other nine 
cases had sIL-2R values within the normal range. There 
was one additional patient with adenocarcinoma 
resected but he had a cerebral metastasis detected 2 
months later. His sIL-2R levels before and at 3 weeks 
after operation were 456 and 1799 U ml-‘, respectively. 
In the 13 patients with tumour resected, one died at 6 
weeks after operation from chest infection compli- 
cated with respiratory failure and another defaulted 
follow up. In the 11 remaining cases, there was no 
evidence of tumour relapse after 6-l 5 months follow 
up (mean 10 months). Their sIL-2R levels before 
operation (598.1&- 66.8 U ml-‘) was not significantly 
different from the levels at 3 weeks (610.7 f 60.6 U ml-‘) 
and 3 months (532.4+ 56.7 U ml-‘) after operation. 
Discussion 
In this study, we attempted to find out the serum 
sIL-2R levels in patients with non-SCLC, their 
relationship with the extent of disease and the changes 
following resection of the lung tumour. We found 
that serum sIL-2R levels were significantly higher in 
patients with non-SCLC compared to control subjects 
(P<O.OOOl). In patients with extensive intrathoracic 
disease detected at operation but without distant 
metastasis, their serum sIL-2R levels also appear to be 
higher than those with localized resectable tumour. 
However, there was no significant difference between 
the sIL-2R levels in those with metastatic disease 
compared to those with localized tumour. 
For patients with the tumour resected, there was 
no significant difference between the pre- and post- 
operative serum sIL-2R levels up to 3 months after 
operation. However, one patient was found to have a 
rise in serum sIL-2R at 3 weeks which preceded the 
subsequent discovery of a cerebral metastasis at 2 
months after operation. Therefore, elevation of serum 
sIL-2R level may occur during tumour relapse as in 
patients with nasopharyngeal carcinoma (7). 
The source of sIL-2R in patients with non-SCLC 
may be the tumour itself or circulating activated 
T-cells (8). Previous studies on adenocarcinoma and 
squamous cell carcinoma have failed to demonstrate 
surface expression of IL-2R in these cell lines (5). 
Therefore activated T lymphocytes are probably the 
major source of sIL-2R in patients with non-SCLC. 
However, the exact role of the activated T lymphocytes 
and sIL-2R in patients with non-SCLC was uncertain. 
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Although we found that patients with extensive 
intrathoracic disease have higher serum sIL-2R levels, 
suggesting T-cell activation in these cases, the sIL-2R 
levels in those with distant metastasis were more vari- 
able. Some had very high levels while some had normal 
values, indicating a wide spectrum of T lymphocyte 
activity in patients with non-SCLC. The paucity of 
correlation between the extent of disease and serum 
sIL-2R level implies that there are probably multiple 
factors influencing the degree of T lymphocyte acti- 
vation in addition to the tumour load. Other possible 
factors may include the immune status of the host, 
expression of antigen by the tumour cells and blood 
supply of the tumour which would affect the contact 
of T lymphocytes with antigen bearing tumour cells. 
Whether these different degrees of T-cell activation 
would affect the response to alternative treatment 
modalities like radiotherapy, chemotherapy or immuno- 
therapy in patients with inoperable non-SCLC awaits 
further elucidation. 
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